Shared on10 Aug 25
Cytosorbents’ consensus price target has been raised from $5.00 to $7.00, reflecting improved profitability with net profit margin rising to 12.34% and a more attractive future P/E of 74.11x. What's in the News New studies demonstrate early and intensive CytoSorb® therapy significantly improves clinical outcomes for sepsis and septic shock patients, with peer-reviewed data showing increased survival rates when used intensively and early.
Shared on24 Apr 25Fair value Decreased 21%
AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.2%.